Le Lézard
Classified in: Health
Subject: ATY

Dentsply Sirona Investor Alert: Hagens Berman Alerts Dentsply Sirona, Inc. Investors to Investigation of Potential Securities Law Violations Connected to SEC Enforcement Inquiry and Management Shakeup

SAN FRANCISCO, Oct. 6, 2017 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors that it is investigating Dentsply Sirona, Inc. (NASDAQ: XRAY) for possible securities law violations.  If you purchased or otherwise acquired securities of Dentsply Sirona before October 3, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:


or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing


Hagens Berman Sobol Shapiro LLP

On August 9, 2017, Dentsply Sirona announced in its Form 10-Q filing that the SEC's Division of Enforcement "has asked the Company to provide documents and information concerning the Company's accounting and disclosures, including its accounting and disclosures relating to transactions with a significant distributor of the Company."  In reaction, Dentsply Sirona's share price fell $5.18, or 8.4%, to close at $56.23 on August 9, 2017.

On October 2, 2017, Dentsply Sirona announced that three top executives tendered their resignations: CEO Jeffrey Slovin, Executive Chairman Bret Wise, and President and Chief Operating Officer Christopher Clark.  This news drove the price of Dentsply Sirona shares down $3.48, or 5.8%, to close at $56.33 on October 2, 2017.

The next day, The Wall Street Journal reported the Company's board forced these executives out.

"We're focused on the matters triggering the SEC's inquiry, the extent of improper accounting if any, and the possible roles of the recently-departed executives," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Dentsply Sirona should consider their options to help in the investigation or take advantage of the SEC Whistleblower Program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email XRAY@hbsslaw.com.

About Hagens Berman 
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 11 offices across the country.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein, 510-725-3000

SOURCE Hagens Berman Sobol Shapiro LLP

These press releases may also interest you

at 12:29
Medical Facilities Corporation ("Medical Facilities" or the "Company") announced today that a cash dividend payment of Cdn$0.09375 per common share will be payable on October 15, 2018 to holders of record of common shares at the close of business on...

at 12:15
The "Hemostats Market by Product (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Gynecology, Neurology, Cardiovascular, Reconstructive), Formulation (Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to...

at 12:14
On 13 September 2018, Cantargia AB (publ) ("Cantargia" or the "Company") announced that Nasdaq Stockholm's Listing Committee had approved the admission of the Company's shares for trading on Nasdaq Stockholm's regulated market. The Swedish prospectus...

at 12:07
Inc. Magazine named Zeel, the Massage On Demand® company and national wellness provider, No. 619 on its annual Inc. 5000 ? the most distinguished ranking of the nation's fastest-growing private companies. The company achieved three-year revenue...

at 12:05
ORHub, Inc. (the "Company" or "ORHub"), a HIPAA compliant, physician-driven digital software company focused on improving profitability and the cost effectiveness of hospitals through real-time smart data and analytics, today announces that ORHub...

at 12:00
The "T-Cell Immunotherapy Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering. The "T-Cell Immunotherapy Market, 2018-2030 (3rd edition)" report features an extensive study of the current market landscape and...

News published on 6 october 2017 at 09:30 and distributed by: